ES2150993T3 - Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih. - Google Patents

Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih.

Info

Publication number
ES2150993T3
ES2150993T3 ES94919207T ES94919207T ES2150993T3 ES 2150993 T3 ES2150993 T3 ES 2150993T3 ES 94919207 T ES94919207 T ES 94919207T ES 94919207 T ES94919207 T ES 94919207T ES 2150993 T3 ES2150993 T3 ES 2150993T3
Authority
ES
Spain
Prior art keywords
hbv
present
analogs
hepatitis
didesoxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919207T
Other languages
English (en)
Inventor
Tai-Shun Lin
Yung-Chi Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES2150993T3 publication Critical patent/ES2150993T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL DESCUBRIMIENTO DE CIERTOS ANALOGOS DE DIDEOXINUCLEOSIDOS QUE CONTIENEN UNA UNIDAD DIDEOXI RIBOFURANOSILILO QUE TIENE UNA CONFIGURACION EN L (OPUESTA A LA CONFIGURACION EN D QUE SE DA DE MODO NATURAL) EXHIBEN ACTIVIDAD INESPERADA CONTRA EL VIRUS DE LA HEPATITIS B (HHBV).EN PARTICULAR, EL COMPUESTO DE ACUERDO CON LA PRESENTE INVENCION MUESTRAS UNA POTENTE INHIBICION DE LA DUPLICACION DEL VIRUS EN COMBINACION CON UNA TOXICIDAD MUY BAJA EN LA CELULAS HUESPED (POR EJEMPLO TEJIDO ANIMAL O HUMANO). LOS COMPUESTOS DE ACUERDO CON LA PRESENTE INVENCION MUESTRA UN UTILIDAD PRIMARIA COMO AGENTES PARA LA INHIBICION DEL CRECIMIENTO O DUPLICACION DE HBV, VIH Y OTROS RETROVIRUS, PREFERENTEMENTE HBV. EL COMPUESTO 1{(2,2-DIDEOXI-BETA-L-RIBOFURANOSIL)}-5-FLUOROCITOSINA SE PRESENTA POR TENER UN POTENTE AGENTE ANTIVIH CON BAJA TOXICIDAD EN CELULAS HUESPEDES.
ES94919207T 1993-05-25 1994-05-23 Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih. Expired - Lifetime ES2150993T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6729993A 1993-05-25 1993-05-25
US08/098,650 US5627160A (en) 1993-05-25 1993-07-28 L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents

Publications (1)

Publication Number Publication Date
ES2150993T3 true ES2150993T3 (es) 2000-12-16

Family

ID=26747712

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919207T Expired - Lifetime ES2150993T3 (es) 1993-05-25 1994-05-23 Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih.

Country Status (14)

Country Link
US (1) US5627160A (es)
EP (1) EP0707481B1 (es)
JP (2) JPH08510747A (es)
KR (1) KR100279953B1 (es)
CN (1) CN1076021C (es)
AT (1) ATE195423T1 (es)
CA (1) CA2163520C (es)
DE (1) DE69425574T2 (es)
DK (1) DK0707481T3 (es)
ES (1) ES2150993T3 (es)
GR (1) GR3034379T3 (es)
HK (1) HK1013257A1 (es)
PT (1) PT707481E (es)
WO (1) WO1994027616A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5512431A (en) * 1994-06-29 1996-04-30 Darwin Molecular Corporation Methods of screening for nucleoside analogs that are incorporated by HIV reverse transcriptase and cause incorrect base pairing
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
WO1996028162A1 (en) * 1995-03-14 1996-09-19 University Of Medicine & Dentistry Of New Jersey New drug combination for the treatment of viral diseases
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
AU722214B2 (en) * 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EP1254911A1 (en) * 1996-10-16 2002-11-06 ICN Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
CZ126799A3 (cs) * 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
SK284054B6 (sk) * 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Substituované triazolové nukleozidy, farmaceutický prostriedok s ich obsahom a ich použitie
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
US6090602A (en) 1998-02-18 2000-07-18 Promelas Research Corporation Levo-monosaccharide in a nucleoside analog for use as an anti-retroviral agent
MXPA01001507A (es) * 1998-08-10 2003-09-10 Novirio Pharmaceuticals Ltd °l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6525191B1 (en) * 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
AU2002255707A1 (en) 2001-03-15 2002-10-03 Trustees Of Boston College, The Selective anti-viral nucleoside chain terminators
RU2310661C2 (ru) * 2002-04-12 2007-11-20 Акиллион Фармасьютикалз, Инк. Способ синтеза бета-l-5-фтор-2', 3'-дидезокси-2', 3'-дидегидроцитидина (бета-l-fd4c)
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
WO2005026186A1 (de) * 2003-09-12 2005-03-24 Max-Delbrück-Centrum für Molekulare Medizin Β-l-nucleoside und ihre verwendung als pharmazeutische mittel zur behandlung viraler erkrankungen
EP2266579A1 (en) 2004-10-19 2010-12-29 Achillion Pharmaceuticals, Inc. Pharmaceutical composition comprising elvucitavine
GB0513835D0 (en) * 2005-07-07 2005-08-10 Medivir Ab HIV inhibitors
RU2443703C2 (ru) 2007-06-18 2012-02-27 Саншайн Лейк Фарма Ко., Лтд Бром-фенил замещенные тиазолилдигидропиримидины
US8816074B2 (en) * 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CA2782524A1 (en) * 2009-12-17 2011-06-23 Novadex Pharmaceuticals Ab 3'-deoxy-3'-methylidene-.beta.-l-nucleosides
CN102234280B (zh) * 2010-04-26 2014-01-08 北京大学 D,l-鸟嘌呤核苷类似物及其制备方法和应用
US10933067B2 (en) 2016-11-16 2021-03-02 National Center For Global Health And Medicine Nucleoside derivative having physiological activity such as antiviral activity
KR102077833B1 (ko) 2018-12-10 2020-02-14 류형준 기능성 식품조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
IL85778A0 (en) * 1987-03-20 1988-09-30 Bristol Myers Co Production of 2',3'-dideoxynucleosides and certain such novel compounds
JPH01100191A (ja) * 1987-10-13 1989-04-18 Sanyo Kokusaku Pulp Co Ltd ２′，３′−ジデオキシシチジン類の製造方法
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
JPH07103149B2 (ja) * 1987-11-30 1995-11-08 ヤマサ醤油株式会社 シトシン誘導体の製造法
JPH02152976A (ja) * 1988-05-06 1990-06-12 Bristol Myers Co ２´，３´―ジデヒドロ―２´，３´―ジデオキシヌクレオシドのプロドラッグ
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
JPH0269476A (ja) * 1988-09-06 1990-03-08 Kohjin Co Ltd ピリミジン誘導体の製法
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US5128458A (en) * 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
CA2135498A1 (en) * 1992-05-13 1993-11-25 Leonid Beigelman Synthesis of nucleotide monomers
DE4224737A1 (de) * 1992-07-27 1994-02-03 Herbert Prof Dr Schott Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung
KR100252451B1 (ko) * 1992-09-01 2000-04-15 피터 지. 스트링거 뉴클레오사이드의아노머화방법
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues

Also Published As

Publication number Publication date
EP0707481A1 (en) 1996-04-24
ATE195423T1 (de) 2000-09-15
EP0707481B1 (en) 2000-08-16
PT707481E (pt) 2001-02-28
DE69425574D1 (en) 2000-09-21
HK1013257A1 (en) 1999-10-22
KR100279953B1 (ko) 2001-02-01
AU7043094A (en) 1994-12-20
EP0707481A4 (es) 1996-05-29
GR3034379T3 (en) 2000-12-29
JP2004244422A (ja) 2004-09-02
DK0707481T3 (da) 2000-10-30
AU693795B2 (en) 1998-07-09
JPH08510747A (ja) 1996-11-12
DE69425574T2 (de) 2001-01-04
US5627160A (en) 1997-05-06
WO1994027616A1 (en) 1994-12-08
CN1076021C (zh) 2001-12-12
CA2163520A1 (en) 1994-12-08
CA2163520C (en) 2006-01-10
CN1100303A (zh) 1995-03-22

Similar Documents

Publication Publication Date Title
ES2150993T3 (es) Analogos de l-2',3'-didesoxi nucleosidos utilizados como agentes anti-hepatitis b (vhb) y anti-vih.
TW374087B (en) L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
IL86040A0 (en) Acid stable dideoxynucleosides,their preparation and pharmaceutical compositions containing them
KR900004735A (ko) 시클로부탄 유도체 및 그 제조방법
ATE328889T1 (de) L-nukleoside zur behandlung des hepatitis-b- und epstein-bar-virus
PA8483101A1 (es) Compuestos quimicos
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
KR890003761A (ko) 치료학적 아시클릭 뉴클레오시드
ES2022883B3 (es) Una composicion desodorante y uso de ella
AU4266189A (en) Use of 1-alkyl azacycloalkanes as insect repellants
AU4408597A (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
KR910000734A (ko) 네플라노신 유도체
ES8605538A1 (es) Procedimiento para la preparacion de nonapeptidos y dodecapeptidos
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
FR2591890B1 (fr) Composition a usage therapeutique comprenant des composes organo-silicies
SE9701912D0 (sv) Pharmaceutical composition and use thereof
WO2002055520A3 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
ES8308335A1 (es) Un procedimiento para la preparacion de nuevos derivados de desoxiuridina.
TW370531B (en) Novel thymidylate analogs and uses thereof
ES2116522T3 (es) Compuestos citotoxicos.
JPS5677226A (en) Antitumorigenic agent
ES2078139B1 (es) Composiciones antirretrovirales que contienen compuestos iodados.
TW217986B (en) Compositions for the treatment of infection and disease caused by HBV
ECSP993155A (es) Compuestos quimicos
KR940703656A (ko) 에이즈 바이러스 감염 저해용 조성물

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 707481

Country of ref document: ES